CN102647990A - 减少功能状态损失的方法 - Google Patents

减少功能状态损失的方法 Download PDF

Info

Publication number
CN102647990A
CN102647990A CN201080041532XA CN201080041532A CN102647990A CN 102647990 A CN102647990 A CN 102647990A CN 201080041532X A CN201080041532X A CN 201080041532XA CN 201080041532 A CN201080041532 A CN 201080041532A CN 102647990 A CN102647990 A CN 102647990A
Authority
CN
China
Prior art keywords
vitamin
bcaa
protein
lactalbumin
nutrition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080041532XA
Other languages
English (en)
Chinese (zh)
Inventor
K·B·米勒
I·A·尤尔克
Z·K·鲁格海德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Societe dAssistance Technique pour Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe dAssistance Technique pour Produits Nestle SA filed Critical Societe dAssistance Technique pour Produits Nestle SA
Publication of CN102647990A publication Critical patent/CN102647990A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
CN201080041532XA 2009-07-20 2010-07-15 减少功能状态损失的方法 Pending CN102647990A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22680609P 2009-07-20 2009-07-20
US61/226,806 2009-07-20
US33424710P 2010-05-13 2010-05-13
US61/334,247 2010-05-13
PCT/US2010/042083 WO2011011252A1 (en) 2009-07-20 2010-07-15 Methods of attenuating the loss of functional status

Publications (1)

Publication Number Publication Date
CN102647990A true CN102647990A (zh) 2012-08-22

Family

ID=42990259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080041532XA Pending CN102647990A (zh) 2009-07-20 2010-07-15 减少功能状态损失的方法

Country Status (13)

Country Link
US (1) US20120195873A1 (enExample)
EP (2) EP3231435A1 (enExample)
JP (1) JP2012533627A (enExample)
CN (1) CN102647990A (enExample)
AU (1) AU2010274125B2 (enExample)
BR (1) BR112012001488A2 (enExample)
CA (1) CA2768471A1 (enExample)
IN (1) IN2012DN00486A (enExample)
MX (1) MX2012000943A (enExample)
RU (1) RU2012105901A (enExample)
SG (1) SG177664A1 (enExample)
WO (1) WO2011011252A1 (enExample)
ZA (1) ZA201201229B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188413A (zh) * 2013-05-01 2015-12-23 雅培公司 增强老化肌肉再生的方法
CN106535662A (zh) * 2014-07-21 2017-03-22 雀巢产品技术援助有限公司 促进患有咽下困难的个体安全吞咽的营养产品
CN106793806A (zh) * 2014-10-14 2017-05-31 雀巢产品技术援助有限公司 对老年男性的肌肉功能的改善
CN108430490A (zh) * 2015-12-03 2018-08-21 株式会社明治 营养组合物
CN109152749A (zh) * 2016-05-27 2019-01-04 雀巢产品技术援助有限公司 用于治疗或预防移动性受损的营养组合物
CN109982585A (zh) * 2016-11-16 2019-07-05 费森尤斯卡比德国有限公司 用于患有肌少症和/或衰弱症的患者或肌少症前期和/或衰弱症前期患者的疗法中的用途的营养组合物
TWI761523B (zh) * 2017-06-01 2022-04-21 日商明治股份有限公司 營養組成物

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544555B1 (en) * 2010-03-12 2018-05-16 Nestec S.A. Compositions for masking the flavor of leucine and methods for making same
JP2013529193A (ja) * 2010-04-26 2013-07-18 ネステク ソシエテ アノニム 非経口栄養から経腸栄養へ離脱させるための栄養組成物及び方法
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
CN103370062A (zh) * 2011-02-25 2013-10-23 默克专利股份有限公司 增强关节和/或姿势稳定性的组合物
BR112013026706A2 (pt) * 2011-04-18 2016-12-27 Nestec Sa composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico
MX2013014428A (es) * 2011-06-08 2014-03-31 Nestec Sa Composiciones nutricionales que tienen componentes exogenos de membrana de globulos de grasa de leche.
JP2013051920A (ja) * 2011-09-05 2013-03-21 Ishikawa Prefectural Public Univ Corp 骨密度強化補助食品
EP2580967A1 (en) 2011-10-11 2013-04-17 Nestec S.A. Accelerating muscle recovery after immobilization-induced muscle atrophy
PL2583566T3 (pl) * 2011-10-21 2016-01-29 Nestec Sa Micele serwatkowego białka do zwiększania masy mięśni i sprawności
EP2583565A1 (en) * 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for enhancing energy expenditure and satiety
EP2583563A1 (en) * 2011-10-21 2013-04-24 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
EP2800478A2 (en) * 2012-01-03 2014-11-12 Nestec S.A. Compositions and methods for the stability of reactive amino acids in a food matrix
RU2520036C2 (ru) * 2012-03-01 2014-06-20 Общество с ограниченной ответственностью "Институт новых технологий" Пищевой продукт "миоактив-спорт" для питания людей, подверженных интенсивным физическим нагрузкам
CA2885388C (en) * 2012-10-04 2018-01-02 Abbott Laboratories Methods for enhancing the effect of egcg on mitigating skeletal muscle loss
CN103783532B (zh) * 2012-10-29 2016-06-08 杭州纽曲星生物科技有限公司 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法
CN103271350B (zh) * 2013-03-04 2014-09-24 中国航天员科研训练中心 空间站航天员太空高能压缩食品及其制法
CN105188695A (zh) 2013-03-14 2015-12-23 雅培制药有限公司 与长期体力活动不足有关的胰岛素抗性的治疗
CN105431057A (zh) 2013-03-15 2016-03-23 雅培制药有限公司 维持和改善肌肉功能的方法
US20160051814A1 (en) * 2013-04-15 2016-02-25 Nestec S.A. Use of whey protein in combination with electrical muscle stimulation
US20140357576A1 (en) * 2013-05-31 2014-12-04 Nestec S.A. Methods for enhancement of muscle protein synthesis
BR112015030767B1 (pt) 2013-06-10 2021-03-30 N.V. Nutricia Uso de uma composição
JP6279851B2 (ja) * 2013-07-19 2018-02-14 雪印メグミルク株式会社 筋萎縮防止及び／又は筋合成促進剤
NO3006027T3 (enExample) * 2014-10-08 2018-04-14
CN107073068A (zh) * 2014-11-19 2017-08-18 雀巢产品技术援助有限公司 使用乳清蛋白胶束和果胶的复合物管理体重
ES2997312T3 (en) * 2015-11-20 2025-02-17 Nestle Sa Composition comprising micellar whey protein, vitamin d and calcium for use in decreasing fat deposition in skeletal muscle in an elderly individual
US10758560B2 (en) 2015-12-22 2020-09-01 Societe Des Produits Nestle S.A. Methods for treating sarcopenia and frailty
JP6848962B2 (ja) * 2016-03-16 2021-03-24 味の素株式会社 行動体力向上剤
AU2016402338A1 (en) * 2016-04-14 2018-11-08 Michael LUCEY Combinational compositions and methods of use thereof
JP6948103B2 (ja) * 2016-04-14 2021-10-13 株式会社明治 フレイル改善用組み合わせ物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CA3052324C (en) 2017-03-03 2020-11-03 Exerkine Corporation Multi-nutrient composition
MA49906A (fr) 2017-08-14 2020-06-24 Axcella Health Inc Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
JP7044306B2 (ja) * 2018-07-31 2022-03-30 ユーハ味覚糖株式会社 ロイシン血中濃度上昇促進剤及びその用途
WO2020120224A1 (en) * 2018-12-13 2020-06-18 Société des Produits Nestlé S.A. Liquid concentrates formulated for dilution into nutritional products to promote safe swallowing for individuals with dysphagia
IL288801B2 (en) * 2019-06-28 2025-02-01 Dompe Farm Spa Preparations containing non-branched chain acids
JP7655224B2 (ja) * 2019-10-25 2025-04-02 味の素株式会社 筋質向上剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2683492B2 (ja) * 1993-09-07 1997-11-26 雪印乳業株式会社 ミセル状ホエー蛋白質、その溶液、その粉末およびミセル状ホエー蛋白質の製造法
CN1101810A (zh) * 1994-08-23 1995-04-26 谢宝兴 茯苓枸杞子口服液饮料袋泡茶及其生产方法
EP1062876A1 (en) * 1999-02-25 2000-12-27 Societe Des Produits Nestle S.A. Caseinoglycomacropeptides as calcification agent
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
US7794770B2 (en) * 2004-10-07 2010-09-14 Next Proteins, Inc. Protein beverage and method of making the same
CA2537647A1 (en) * 2005-03-01 2006-09-01 Six Star Formulations Ltd. Supplemental dietary composition for supporting muscle growth, recovery and strength
FR2882896B1 (fr) * 2005-03-14 2007-05-04 Larena Sa Composition alimentaire pour prevenir le syndrome de fragilite chez les personnes agees
US20070020358A1 (en) * 2005-03-18 2007-01-25 Mower Thomas E Sports drink concentrate
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
CA2621739A1 (en) * 2005-09-09 2007-03-15 Murray Goulburn Co-Operative Co. Limited Composition of whey growth factor extract for reducing muscle inflammation
ES2359255T3 (es) * 2006-03-27 2011-05-19 Nestec S.A. Postre congelado enriquecido con proteínas.
ES2322181T3 (es) * 2006-03-27 2009-06-17 Nestec S.A. Preparacion in situ de micelas de proteinas de suero de leche.
BRPI0718384A2 (pt) * 2006-10-19 2013-11-12 Nestec Sa Alimentação a longo prazo para pacientes com câncer
AR060847A1 (es) 2007-05-03 2008-07-16 Spannagel Lucia Antonia Formulacion a base de calendula, aloe y centella.
WO2009143097A1 (en) * 2008-05-21 2009-11-26 Stokely-Van Camp, Inc. Milk-based recovery beverage
WO2010002242A1 (en) * 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LARS HOLM等: "Protein-containing nutrient supplementation following strength training enhances the effect on muscle mass, strength, and bone formation in postmenopausal women", 《JOURNAL OF APPLIED PHYSIOLOGY》 *
任雁等: "浅谈运动营养强化剂", 《中国食品添加剂》 *
纪慧君等: "运动营养补剂的使用原则和种类", 《冰雪运动》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188413A (zh) * 2013-05-01 2015-12-23 雅培公司 增强老化肌肉再生的方法
CN106535662A (zh) * 2014-07-21 2017-03-22 雀巢产品技术援助有限公司 促进患有咽下困难的个体安全吞咽的营养产品
CN106793806A (zh) * 2014-10-14 2017-05-31 雀巢产品技术援助有限公司 对老年男性的肌肉功能的改善
CN108430490A (zh) * 2015-12-03 2018-08-21 株式会社明治 营养组合物
TWI712367B (zh) * 2015-12-03 2020-12-11 日商明治股份有限公司 營養組成物
CN109152749A (zh) * 2016-05-27 2019-01-04 雀巢产品技术援助有限公司 用于治疗或预防移动性受损的营养组合物
CN109982585A (zh) * 2016-11-16 2019-07-05 费森尤斯卡比德国有限公司 用于患有肌少症和/或衰弱症的患者或肌少症前期和/或衰弱症前期患者的疗法中的用途的营养组合物
US11612578B2 (en) 2016-11-16 2023-03-28 Fresenius Kabi Deutschland Gmbh Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
CN109982585B (zh) * 2016-11-16 2024-03-15 费森尤斯卡比德国有限公司 用于患有肌少症和/或衰弱症的患者或肌少症前期和/或衰弱症前期患者的疗法中的用途的营养组合物
TWI761523B (zh) * 2017-06-01 2022-04-21 日商明治股份有限公司 營養組成物

Also Published As

Publication number Publication date
EP2456448A1 (en) 2012-05-30
IN2012DN00486A (enExample) 2015-05-22
EP3231435A1 (en) 2017-10-18
ZA201201229B (en) 2013-07-31
AU2010274125A1 (en) 2012-02-16
RU2012105901A (ru) 2013-08-27
US20120195873A1 (en) 2012-08-02
CA2768471A1 (en) 2011-01-27
SG177664A1 (en) 2012-02-28
BR112012001488A2 (pt) 2019-10-08
MX2012000943A (es) 2012-02-28
AU2010274125B2 (en) 2015-11-05
WO2011011252A1 (en) 2011-01-27
JP2012533627A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
AU2010274125B2 (en) Methods of attenuating the loss of functional status
JP7210459B2 (ja) 老化防止剤及び老化防止方法
ES2832506T3 (es) Composiciones que comprenden ribósido de nicotinamida y una urolitina
CN105101812B (zh) 大米蛋白补充剂
US9961932B2 (en) Muscle preservation in overweight or obese adult during weight loss program
ES2994610T3 (en) Compositions comprising an urolithin compound
WO2012024611A1 (en) Methods of treating sarcopenia and frailty
ES2857652T3 (es) Principio activo para el tratamiento de la sarcopenia
US11173167B2 (en) Nutritional intervention for improving muscular function and strength
Serafini et al. Nutritional approach to sarcopenia
US20230149426A1 (en) Nutritional Intervention for Improving Muscular Function and Strength
Dovbish Natural Product Trends
US20210393559A1 (en) Compositions and Methods of Use of Beta-Hydroxy-Beta-methylbutyrate (HMB) for Improving Muscle Mass, Strength and Muscular Function Without Exercise
WO2025166466A1 (en) A method to treat body composition resistance
Al-Sinbil et al. Effect of oral intake of L-carnitine and L-arginine supplements on Growth hormone and Dopamine level in Sportsmen pre-and post-exercise
HK1213441B (en) Rice protein supplements
MATHENA What is MSM?
JPWO1997043912A1 (ja) 体脂肪率低下体組成改善食組成物及び体脂肪率低下体組成改善方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120822